tiprankstipranks
Scribe Therapeutics Inc. (SCTX)
NASDAQ:SCTX
US Market

Scribe Therapeutics Inc. (SCTX) Price & Analysis

2 Followers

SCTX Stock Chart & Stats

$21.65
--
--

SCTX FAQ

What was Scribe Therapeutics Inc.’s price range in the past 12 months?
Scribe Therapeutics Inc. lowest stock price was $21.00 and its highest was $25.49 in the past 12 months.
    What is Scribe Therapeutics Inc.’s market cap?
    Scribe Therapeutics Inc.’s market cap is $350.34M.
      When is Scribe Therapeutics Inc.’s upcoming earnings report date?
      The company’s upcoming earnings report date is not yet available.
      How were Scribe Therapeutics Inc.’s earnings last quarter?
      Currently, no data Available
      Is Scribe Therapeutics Inc. overvalued?
      According to Wall Street analysts Scribe Therapeutics Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
        Does Scribe Therapeutics Inc. pay dividends?
        Scribe Therapeutics Inc. does not currently pay dividends.
        What is Scribe Therapeutics Inc.’s EPS estimate?
        Scribe Therapeutics Inc.’s EPS estimate for its next earnings report is not yet available.
        How many shares outstanding does Scribe Therapeutics Inc. have?
        Scribe Therapeutics Inc. has 16,182,010 shares outstanding.
          What happened to Scribe Therapeutics Inc.’s price movement after its last earnings report?
          Currently, no data Available
          Which hedge fund is a major shareholder of Scribe Therapeutics Inc.?
          Currently, no hedge funds are holding shares in SCTX
          What is the TipRanks Smart Score and how is it calculated?
          Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

            Company Description

            Scribe Therapeutics Inc.

            Scribe Therapeutics is a clinical-stage biotechnology company focused on developing in vivo CRISPR-based genetic medicines. The company engineers proprietary technologies to target the genetic drivers of disease, with an initial focus on atherosclerotic cardiovascular disease (ASCVD), aiming to shift treatment from chronic care to preventative intervention.
            Popular Stocks